Consensus recommendations for optimizing biomarker testing to identify and treat advanced EGFR-mutated non-small-cell lung cancer

The advent of personalized therapy for non-small-cell lung carcinoma (nsclc) has improved patient outcomes. Selection of appropriate targeted therapy for patients with nsclc now involves testing for multiple biomarkers, including EGFR. EGFR mutation status is required to optimally treat patients wit...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Curr Oncol
Glavni autori: Cheema, P.K., Gomes, M., Banerji, S., Joubert, P., Leighl, N.B., Melosky, B., Sheffield, B.S., Stockley, T., Ionescu, D.N.
Format: Artigo
Jezik:Inglês
Izdano: Multimed Inc. 2020
Teme:
Practice Guideline
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7755440/
https://ncbi.nlm.nih.gov/pubmed/33380864
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.27.7297
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items